摘要

The Advisory Committee on Immunization Practices concluded that the benefits of resuming Janssen COVID-19 vaccination among persons aged ≥18 years outweighed the risks and reaffirmed its interim recommendation under FDA’s Emergency Use Authorization, which includes a new warning for rare clotting events among women aged 18-49 years.

詳細內容

The Advisory Committee on Immunization Practices concluded that the benefits of resuming Janssen COVID-19 vaccination among persons aged ≥18 years outweighed the risks and reaffirmed its interim recommendation under FDA’s Emergency Use Authorization, which includes a new warning for rare clotting events among women aged 18-49 years.

關鍵發現

(需要透過 WebFetch 補充或人工審核來提取關鍵發現)

---

萃取時間: 2026-02-05T15:14:02Z 資料來源: CDC MMWR